---
schema_version: "secwatch.filing_event.v1"
accession: "0001599298-26-000067"
form_type: "8-K"
ticker: "SMMT"
cik: "0001599298"
company_name: "Summit Therapeutics Inc."
filed_at: "2026-07-23T20:07:41+00:00"
generated_at: "2026-07-23T20:09:24.654319+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Summit Therapeutics Q2 2026: Cash $690.7M; HARMONi-6 OS benefit; PDUFA Nov 14

## Summary
- Cash and investments $690.7M at June 30, 2026; raised $230.8M via ATM in Q2 and $68.4M post-quarter.
- GAAP net loss $215.7M ($0.28/share); Non-GAAP net loss $147.0M ($0.19/share) vs $86.9M ($0.12) in Q2 2025.
- HARMONi updated OS: HR 0.76 in full ITT, consistent in western and Asian patients; BLA PDUFA Nov 14, 2026.
- HARMONi-6 (Akeso) showed OS benefit over tislelizumab (HR 0.66, p=0.0017) in 1L squamous NSCLC.
- Sold ridinilazole to Biossil for $500K upfront + up to $104.5M milestones; clinical collaborations with Arcus, RevMed, GSK.

## SEC filing metadata
- accession: 0001599298-26-000067
- form_type: 8-K
- ticker: SMMT
- cik: 0001599298
- company_name: Summit Therapeutics Inc.
- filed_at: 2026-07-23T20:07:41+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1599298/000159929826000067/0001599298-26-000067-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1599298/000159929826000067/smmt-20260723.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001599298-26-000067
- JSON: https://secwatch.observer/filing/0001599298-26-000067.json
- Plain text: https://secwatch.observer/filing/0001599298-26-000067.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.